Exelixis, Inc. (LON:0IJO)

Market Cap	8.17B +9.2%
Revenue (ttm)	1.72B +9.9%
Net Income	581.45M +45.2%
EPS	2.07 +53.5%
Shares Out	n/a
PE Ratio	14.06
Forward PE	12.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,407
Average Volume	1,505
Open	42.51
Previous Close	42.59
Day's Range	42.45 - 43.40
52-Week Range	32.42 - 51.98
Beta	0.40
RSI	47.31
Earnings Date	Jan 13, 2026

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1994
• Employees: 1,077
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IJO

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD